Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.

摘要: Next-generation sequencing (NGS) capabilities can affect therapeutic decisions in patients with complex, advanced, or refractory cancer. We report the feasibility of a tumor advisory board at regional cancer center. Specimens were analyzed for approximately 2800 mutations 50 genes. Outcomes interest included function and processes, timely discussion results, proportion reports having potentially actionable mutations. NGS results successfully generated 15 patients, median time from tissue processing to reporting 11.6 days (range, 5 21 days), presented biweekly multidisciplinary board. Attendance averaged 19 participants 12 24) 20 after patient enrollment 10 30 days). Twenty-seven 1 4 per patient) detected 11 patients: TP53 (n = 6), KRAS (n = 4), MET 3), APC CDKN2A 2), PTEN PIK3CA, FLT3, NRAS, VHL, BRAF, SMAD4, ATM. The Hotspot Panel is now offered as clinically available test our institution. be obtained by in-house high-throughput reviewed relevant manner. essential components center personalized care support clinical outside university.